Reversible parkinsonism and cognitive impairment with chronic valproate use
- 1 September 1996
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 47 (3) , 626-635
- https://doi.org/10.1212/wnl.47.3.626
Abstract
Following our initial report of the insidious development of reversible, valproate-induced hearing, motor, and cognitive dysfunction in two patients, we evaluated 36 patients in an epilepsy clinic who had been taking therapeutic levels of valproate for at least 12 months; 29 of these patients were examined according to a prospective protocol. We observed varying degrees of parkinsonism and cognitive impairment, from none to severe. Discontinuation of valproate in 32 affected patients led to subjective and objective improvement on follow-up testing at least 3 months later. Improvement was greatest in patients who were affected most. We conclude that a syndrome of reversible parkinsonism and cognitive impairment may develop insidiously in patients who have been treated with valproate for more than 12 months. The association with valproate may be overlooked due to the insidious onset. NEUROLOGY 1996;47: 626-635Keywords
This publication has 6 references indexed in Scilit:
- Apolipoprotein E genotyping in the differential diagnosis, not prediction, of Alzheimer's diseaseAnnals of Neurology, 1995
- Influenza A Virus‐Specific Cytotoxic T Lymphocyte Activity Declines with Advancing AgeJournal of the American Geriatrics Society, 1993
- Temperature dependence of transcriptional activity of yeast 3-phosphoglycerokinase promoter in Escherichia coliBiochemical and Biophysical Research Communications, 1990
- The Lewy body variant of Alzheimer's diseaseNeurology, 1990
- Proteolytic activities of human Campylobacter pylori and ferret gastric Campylobacter-like organismBiochemical and Biophysical Research Communications, 1989
- Huntington diseaseNeurology, 1979